An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

NCT02970929 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

157

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: SEP-363856

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.